Wednesday - April 2, 2025
Novo Nordisk Enters License Agreement with Lexicon Pharmaceuticals for Oral Obesity Drug in Deal Valued at Up to $1 Billion
March 31, 2025
BOSTON, Massachusetts, March 31 [Category: BizLaw/Legal] -- Ropes and Gray, a law firm, issued the following news:

* * *

Novo Nordisk Enters License Agreement with Lexicon Pharmaceuticals for Oral Obesity Drug in Deal Valued at Up to $1 Billion

Ropes & Gray advised Novo Nordisk in an exclusive license agreement with Lexicon Pharmaceuticals for LX9851, a first-in-class oral drug candidate for obesity and related metabolic disorders. The deal was announce . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products